Benzodiazepine Use in COPD: Increased Risk of Adverse Respiratory Outcomes
Benzodiazepine use in patients with COPD is associated with significantly increased risk of respiratory exacerbations, emergency room visits, hospitalizations, and mortality, and should be avoided whenever possible. 1
The Evidence on Harm
The correlation between COPD and benzodiazepine use is well-established and concerning:
Increased Respiratory Events
- Benzodiazepine use alone increases risk of outpatient respiratory exacerbations by 45% (RR 1.45) and emergency room visits for COPD or pneumonia by 92% (RR 1.92) within 30 days of use 2
- Among older adults with COPD, benzodiazepine use alone increases hospitalization risk by 42% (aOR 1.42), while opioid use alone increases it by 73% (aOR 1.73) 3
- Concurrent opioid and benzodiazepine use more than doubles hospitalization risk (aOR 2.32) compared to no use, with even greater risk in patients with high-complexity COPD 3
Mortality Concerns
- The most recent Cochrane review demonstrates lack of evidence either for or against benzodiazepines for breathlessness, but benzodiazepine use has been associated with increased risk of all-cause mortality in severe COPD 1
- Long-term benzodiazepine use (≥90 days) in COPD patients with PTSD showed increased suicide risk (HR 2.33) 4
- Short-term benzodiazepine use carries higher mortality risk (HR 1.16) than long-term use, possibly due to acute respiratory depression effects 4
Additional Morbidity
- Benzodiazepines increase risk of falls, drowsiness, somnolence, and respiratory tract infections in COPD patients 5
- The longer patients take benzodiazepines, the more likely they become dependent 5
Clinical Context: Why Benzodiazepines Are Prescribed
COPD is frequently associated with multiple comorbidities including depression, anxiety, and sleep disorders 6. These symptoms are particularly prevalent later in the disease course, leading clinicians to prescribe benzodiazepines for:
- Anxiety management
- Sleep disorders/insomnia
- Chronic breathlessness (though evidence for this indication is lacking)
The prevalence of benzodiazepine prescribing in COPD has increased dramatically—from 4.6% of visits during 1999-2002 to 10.2% during 2007-2010 7, with patients with COPD being 48% more likely to receive benzodiazepines than those without COPD 7.
Recommended Approach
When Benzodiazepines Should Be Avoided
- First-line or routine use for anxiety, insomnia, or breathlessness in COPD patients
- Concurrent use with opioids (which quadruples overdose death risk in general populations) 8
- Long-term use (dependency risk increases with duration) 5
When Benzodiazepines Might Be Considered (Second- or Third-Line Only)
Benzodiazepines should only be used as second- or third-line therapy, in acute episodes when other measures have failed and anxiety significantly aggravates distress 1. Even then:
- Use the lowest effective dose
- Prescribe for the briefest time possible (short-term use only)
- Discontinue when possible
- Avoid longer-acting compounds in favor of shorter-acting ones 5
Evidence-Based Alternatives
For anxiety:
- Evidence-based psychotherapies (e.g., cognitive behavioral therapy)
- Specific antidepressants (SSRIs/SNRIs)
- Other non-benzodiazepine medications approved for anxiety 8
- Combination of opioid + SSRI/SNRI shows decreased ER visit risk (HR 0.84) in COPD patients with comorbid pain and anxiety 9
For insomnia:
- Melatonin
- Trazodone
- Doxepin
- Note: Even non-benzodiazepine hypnotics like zolpidem may carry similar risks 10
For chronic breathlessness:
- Low-dose opioids (morphine 10 mg/day, titrated to maximum 30 mg/day) are the only licensed treatment for chronic breathlessness 1
- Opioids combined with gabapentinoids show decreased risk for both ER visits (HR 0.73) and hospitalization (HR 0.69) in COPD patients with chronic pain 9
Critical Pitfalls to Avoid
Don't assume benzodiazepines are safe for breathlessness—there is no evidence supporting their use for this indication 1
Don't combine benzodiazepines with opioids—this combination dramatically increases respiratory depression and mortality risk 8, 3, 11
Don't prescribe long-term without reassessment—short-term use may actually carry higher acute mortality risk than established long-term use, but long-term use increases dependency 4
Don't ignore the "healthy user effect"—patients tolerating long-term benzodiazepines may represent a selected population with lower baseline risk 11
Recognize confounding by indication—patients prescribed benzodiazepines often have more severe symptoms and comorbidities, but the drugs themselves independently increase risk 2, 10